In order to facilitate optimal detection and assessment of liver fibrosis and steatosis, the newly launched Hepatus 6 Diagnostic Ultrasound System offers the capabilities of real-time two-dimensional ultrasound with visual transient elastography in one device.
Offering a variety of automated tools and enhanced diagnostic functionality to aid in the diagnosis and quantification of liver fibrosis and steatosis, Minday has launched the Hepatus 6 Diagnostic Ultrasound System.
In addition to the benefits of two-dimensional (2D) and color Doppler imaging for the assessment of liver morphology, Mindray said the Hepatus 6 Diagnostic Ultrasound System provides access to visual transient elastography (ViTE) in the same device.
Automated features include quantitative analysis of liver stiffness, liver ultrasound attenuation analysis and one-click capture of 10 automated Q-scan measurements of fibrosis and steatosis within seconds, according to Mindray.
“The Hepatus 6 system provides clinicians a clear view of patient liver health and helps create a clear path forward for patients with chronic liver disease like no other system on the market today,” noted Wayne Quinn, the president of Mindray North America.
Mindray said another aspect of the Hepatus 6 Diagnostic Ultrasound System includes the ability to switch between the ViTE transducer and the curved ultrasound transducer to see greater real-time detail. The company added that an adjustable panel facilitates ergonomic workflow.
(Editor’s note: For related content, see “MRI Study Shows Higher Fibrosis Risk Among First-Degree Relatives of People with NAFLD and Advanced Fibrosis” and “Can Deep Learning Enhance Ultrasound Assessment of Hepatic Steatosis in Patients with NAFLD?”)
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.